Guth et al. demonstrated that RAN (i) inhibited tumor development and (ii) boosted anti-cancer immunity, as shown by reduced tumor CD8+ T-cells Tim3 content, enhanced macrophages, and lowered blood myeloid immunosuppressive monocytes in the TRAMPC1 genetic mice model of prostate cancer [22]. Here, HAVCR2 is linked to neoplasm.